Suppr超能文献

台湾地区髋部骨折患者应用抗骨质疏松药物的临床结局、医疗支出及骨密度证据要求的影响

Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan.

机构信息

School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.

Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.

出版信息

Int J Health Policy Manag. 2022 Apr 1;11(4):470-478. doi: 10.34172/ijhpm.2020.169.

Abstract

BACKGROUND

Since 2011, Taiwan's National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated medical expenditures of patients with incident hip fractures.

METHODS

By using the National Health Insurance Research Database (NHIRD), patients with incident hip fracture from 2006 to 2015 were identified as our study cohort. Patients younger than 50 years old or prescribed with AOMs within one year prior to incident fracture were excluded. Outcomes of interest were quarterly estimates of the proportion of patients who received bone mineral density (BMD) examination, who were prescribed AOMs, as well as who encountered subsequent osteoporotic fracture-related visits and associated medical expenditures. Particularly, age- and gender specific estimates were reported. An interrupted time series study design with segmented regression model was used to quantitatively explore the impact of the changes of the reimbursement criteria on the level (immediate) and trend (long-term) changes of these outcomes.

RESULTS

Our study enrolled 118 493 patients with incident hip fracture with those patients aged older than 80 years old accounting for the largest proportion. A significantly decreased trend of AOMs prescription rates was observed immediately post regulation except for female aged between 65 and 80, while the long-term pattern showed no significant difference. However, the percentage of patients encountered subsequent osteoporotic fracture-related visit was not statistically different between pre- and post-regulation periods. Noteworthy, the policy regulation was associated with an increasing trend of osteoporotic fracture associated medical expenditures, especially for patients older than 80 years old.

CONCLUSION

The regulation on the reimbursement for AOMs decreased the prescribing rate of AOMs immediately although the effect did not sustain thereafter. However, higher subsequent osteoporotic fracture-related medical expenditures were introduced, especially among those very old population.

摘要

背景

自 2011 年起,台湾地区全民健康保险署(NHIA)发布了一项关于抗骨质疏松药物(AOM)报销的规定。本研究旨在评估该报销规定对新诊断髋部骨折患者 AOM 使用、临床结局和相关医疗支出的影响。

方法

利用全民健康保险研究数据库(NHIRD),确定 2006 年至 2015 年间患有新发髋部骨折的患者作为我们的研究队列。排除年龄小于 50 岁或在骨折前一年内服用 AOM 的患者。感兴趣的结果是每季度接受骨密度(BMD)检查、服用 AOM 以及发生后续骨质疏松性骨折相关就诊和相关医疗支出的患者比例的估计值。特别是,报告了按年龄和性别划分的估计值。采用中断时间序列研究设计和分段回归模型,定量探讨报销标准变化对这些结果的水平(即时)和趋势(长期)变化的影响。

结果

本研究共纳入 118493 例新发髋部骨折患者,其中年龄大于 80 岁的患者比例最大。除了 65-80 岁的女性外,监管后即刻 AOM 处方率呈显著下降趋势,而长期模式无显著差异。然而,监管前后的后续骨质疏松性骨折相关就诊率无统计学差异。值得注意的是,该政策法规与骨质疏松性骨折相关医疗支出的增加趋势有关,特别是对于年龄大于 80 岁的患者。

结论

该 AOM 报销规定虽可降低 AOM 的处方率,但该效果无法持续。然而,引入了更高的后续骨质疏松性骨折相关医疗支出,尤其是在非常高龄人群中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验